摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

hydroxy-di-thiophen-2-yl-acetic acid (1S,2R,4S,7S)-7-((9-((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)methyl-amino)bicyclo[2.2.1]hept-2-yl ester | 925700-57-8

中文名称
——
中文别名
——
英文名称
hydroxy-di-thiophen-2-yl-acetic acid (1S,2R,4S,7S)-7-((9-((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)methyl-amino)bicyclo[2.2.1]hept-2-yl ester
英文别名
anti-hydroxy-di-thiophen-2-yl-acetic acid (1S,2R,4S)-7-({9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinolin-5-yl)-ethylamino]-nonyl}-methyl-amino)-bicyclo[2.2.1]hept-2-yl ester;Hydroxy-di-thiophen-2-yl-acetic acid (1S,2R,4S,7S)-7-({9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinolin-5-yl)-ethylamino]-nonyl}-methyl-amino)-bicyclo[2.2.1]hept-2-yl ester;[(1S,2R,4S,7S)-7-[9-[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]nonyl-methylamino]-2-bicyclo[2.2.1]heptanyl] 2-hydroxy-2,2-dithiophen-2-ylacetate
hydroxy-di-thiophen-2-yl-acetic acid (1S,2R,4S,7S)-7-((9-((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)methyl-amino)bicyclo[2.2.1]hept-2-yl ester化学式
CAS
925700-57-8
化学式
C38H49N3O6S2
mdl
——
分子量
707.956
InChiKey
LIXPLYKBOKTRBL-WMLPZMRVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    49
  • 可旋转键数:
    19
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    188
  • 氢给体数:
    5
  • 氢受体数:
    10

反应信息

点击查看最新优质反应信息

文献信息

  • Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses
    申请人:Finch Harry
    公开号:US20100144852A1
    公开(公告)日:2010-06-10
    Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R 12 )—; (i) R 1 is C 1 -C 6 -alkyl or a hydrogen atom; and R 2 is a hydrogen atom or a group —R 5 , —Z—Y—R 5 —Z—NR 9 R 10 ; —Z—CO—NR 9 R 10 ; —Z—NR 9 —CO—R 5 ; or —Z—CO 2 H; and R 3 is a lone pair, or C 1 -C 6 -alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R 1 and R 3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R 2 is a hydrogen atom; or a group —R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 , —Z—CO—NR 9 R 10 , —Z—NR 9 —CO—R 5 , or —Z—CO 2 H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R 1 and R 2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 ; —Z—CO—NR 9 R 10 ; —Z—NR 9 —CO—R 5 ; or —Z—CO 2 H and R 3 is a lone pair, or C 1 -C 6 -alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; R 4 is a group of formula (a), (b), (c) or (d); is an C 1 -C 6 -alkyl, aryl, aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C 1 -C 8 -alkyl)-, heteroaryl(C 1 -C 8 -alkyl)-, cycloalkyl or heterocycloalkyl group, and the remaining variables are as defined in the specification.
    式(I)的化合物具有肌动蛋白M3受体调节活性;其中A是氧原子或基团-N(R12)-; (i) R1是C1-C6-烷基或氢原子;R2是氢原子或基团-R5、-Z-Y-R5-Z-NR9R10、-Z-CO-NR9R10、-Z-NR9-CO-R5或-Z-CO2H;R3是孤对电子,或C1-C6-烷基,此时它连接的氮原子是季氮并带有正电荷;或者(ii) R1和R3与它们连接的氮形成杂环烷基环,R2是氢原子;或者是一个基团-R5、-Z-Y-R5、-Z-NR9R10、-Z-CO-NR9R10、-Z-NR9-CO-R5或-Z-CO2H,此时连接它的氮原子是季氮并带有正电荷;或者(iii) R1和R2与它们连接的氮形成杂环烷基环,所述环被基团-Y-R5、-Z-Y-R5、-Z-NR9R10、-Z-CO-NR9R10、-Z-NR9-CO-R5或-Z-CO2H取代,R3是孤对电子,或C1-C6-烷基,此时连接它的氮原子是季氮并带有正电荷;R4是式(a)、(b)、(c)或(d)的基团;是C1-C6-烷基、芳基、芳基融合环烷基、芳基融合杂环烷基、杂环芳基、芳基(C1-C8-烷基)-、杂环芳基(C1-C8-烷基)-、环烷基或杂环烷基基团,其余变量如说明书所定义。
  • Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
    申请人:Argenta Discovery Limited
    公开号:US07994211B2
    公开(公告)日:2011-08-09
    Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R12)—; (i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group —R5, —Z—Y—R5—Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2 is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; R4 is a group of formula (a), (b), (c) or (d); is an C1-C6-alkyl, aryl, aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C1-C8-alkyl)-, heteroaryl(C1-C8-alkyl)-, cycloalkyl or heterocycloalkyl group, and the remaining variables are as defined in the specification.
    化合物(I)的公式具有肌动蛋白M3受体调节活性;其中公式(I)中,A是氧原子或基团-N(R12)-;(i) R1是C1-C6烷基或氢原子;R2是氢原子或基团-R5,-Z-Y-R5-Z-NR9R10; -Z-CO-NR9R10; -Z-NR9-CO-R5; 或-Z-CO2H;R3是孤对电子或C1-C6烷基,在这种情况下,它附着的氮原子是季氮并带有正电荷;或(ii) R1和R3与它们附着的氮形成杂环烷基环,R2是氢原子;或基团-R5,-Z-Y-R5,-Z-NR9R10,-Z-CO-NR9R10,-Z-NR9-CO-R5或-Z-CO2H,在这些情况下,它附着的氮原子是季氮并带有正电荷;或(iii) R1和R2与它们附着的氮形成杂环烷基环,该环被基团-Y-R5,-Z-Y-R5,-Z-NR9R10,-Z-CO-NR9R10,-Z-NR9-CO-R5或-Z-CO2H取代,R3是孤对电子或C1-C6烷基,在这种情况下,它附着的氮原子是季氮并带有正电荷;R4是公式(a),(b),(c)或(d)的基团;是C1-C6烷基,芳基,芳基融合环烷基,芳基融合杂环烷基,杂芳基,芳基(C1-C8烷基)-,杂芳基(C1-C8烷基)-,环烷基或杂环烷基基团,其余变量如规范所定义。
  • BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES
    申请人:Finch Harry
    公开号:US20110319446A1
    公开(公告)日:2011-12-29
    Compounds of formula (I) have muscarinic M3 receptor modulating activity; wherein A is an oxygen atom or group —N(R 12 )—; (i) R 1 is C 1 -C 6 -alkyl or a hydrogen atom; and R 2 is a hydrogen atom or a group —R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 ; —Z—CO—NR 9 R 10 ; —Z—NR 9 —CO—R 5 ; or —Z—CO 2 H; and R 3 is a lone pair, or C 1 -C 6 -alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R 1 and R 3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R 2 is a hydrogen atom; or a group —R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 , —Z—CO—NR 9 R 10 , —Z—NR 9 —CO—R 5 , or —Z—CO 2 H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R 1 and R 2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 ; —Z—CO—NR 9 R 10 ; —Z—NR 9 —CO—R 5 ; or —Z—CO 2 H and R 3 is a lone pair, or C 1 -C 6 -alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; R 4 is a group of formula (a), (b), (c) or (d); is an C 1 -C 6 -alkyl, aryl, aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C 1 -C 8 -alkyl)-, heteroaryl(C 1 -C 8 -alkyl)-, cycloalkyl or heterocycloalkyl group, and the remaining variables are as defined in the specification.
    式(I)的化合物具有肌动蛋白M3受体调节活性;其中A是氧原子或基团—N(R12)—;(i) R1是C1-C6烷基或氢原子;R2是氢原子或基团—R5、—Z—Y—R5、—Z—NR9R10、—Z—CO—NR9R10、—Z—NR9—CO—R5或—Z—CO2H;R3是孤对电子,或C1-C6烷基,此时它所连接的氮原子是季氮并带正电荷;或(ii) R1和R3与它们所连接的氮共同形成杂环烷基环,R2是氢原子;或基团—R5、—Z—Y—R5、—Z—NR9R10、—Z—CO—NR9R10、—Z—NR9—CO—R5或—Z—CO2H,此时它所连接的氮原子是季氮并带正电荷;或(iii) R1和R2与它们所连接的氮共同形成杂环烷基环,所述环被基团—Y—R5、—Z—Y—R5、—Z—NR9R10、—Z—CO—NR9R10、—Z—NR9—CO—R5或—Z—CO2H取代,R3是孤对电子,或C1-C6烷基,此时它所连接的氮原子是季氮并带正电荷;R4是式(a)、(b)、(c)或(d)的基团;是C1-C6烷基、芳基、芳基螺环烷基、芳基螺杂环烷基、杂芳基、芳基(C1-C8烷基)-、杂芳基(C1-C8烷基)-、环烷基或杂环烷基基团,其余变量如规范所定义。
  • US7994211B2
    申请人:——
    公开号:US7994211B2
    公开(公告)日:2011-08-09
查看更多